Cradle, an Amsterdam, the Netherlands-based provider of a platform for AI-powered protein engineering, raised $73M in Series B funding.
The round was led by IVP with participation from previous investors Index Ventures and Kindred Capital.
The company intends to use the funds to accelerate development efforts.
Led by CEO Stef van Grieken, Cradle provides a machine-learning platform that helps scientists to speed up the development of new therapeutics and bio-based products such as enzymes, antibodies and bio-based materials and chemicals. The platform is also adaptable across multiple assets and use cases for both pharmaceutical and industrial applications including enzymes, antibodies, peptides, vaccines, and therapeutic proteins.
Industry leaders such as Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis and Grifols use its generative AI platform for research and development across therapeutics, diagnostics, food, chemical, and agricultural products.
Cradle recently appointed life sciences industry veteran Sam Partovi as Chief Commercial Officer, the company’s 40th hire, to help expand Cradle’s impact in the biotech sector.
FinSMEs
26/11/2024